Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

Last updated: July 2, 2025
Sponsor: University of Alberta
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hypogammaglobulinemia

Treatment

Immune Globulin Subcutaneous (Human), 20% Solution

Immune Globulin Intravenous (Human), 10%

Clinical Study ID

NCT06989541
HREBA.CC-24-0422
  • Ages > 18
  • All Genders

Study Summary

Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells. These cells are designed to look for a marker called CD19, which is found on both cancer cells and healthy B cells (a type of white blood cell). Because of this, CAR T cells can also destroy healthy B cells. This can lead to a strong drop in B cells and cause a condition called hypogammaglobulinemia (HGG), which makes it harder for the body to fight infections. Serious infections are common in people treated with CAR T cells and are a major reason for death that is not caused by the return of cancer.

To help prevent infections, patients with HGG often get immunoglobulin replacement therapy (IRT), which gives them the antibodies they need. This treatment can be given through a vein (IVIG) or under the skin (SCIG). The goal of this project is to study how often these patients get bacterial infections, how they feel about their quality of life and treatment, and what side effects they may have when treated with IVIG or SCIG after CAR T-cell therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years

  2. Severe HGG defined as total IgG <4 g/L (after subtracting the IgG paraproteinfraction, if present)

  3. Treated with CD19 targeted CAR T cell therapy in the past 6 months

  4. Consent to receive plasma-derived productions

  5. Ability to provide informed consent

Exclusion

Exclusion Criteria:

  1. Inability to comply with study procedures

  2. Pregnancy or planning to conceive

  3. Breastfeeding

  4. Protein-losing conditions that may contribute to HGG (e.g., protein-losingenteropathy, nephrotic syndrome)

  5. SCIG infusion in the prior 3 months.

  6. History of allergy or severe reactions to immune globulin productions

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Immune Globulin Subcutaneous (Human), 20% Solution
Phase:
Study Start date:
June 01, 2025
Estimated Completion Date:
May 01, 2027

Study Description

Chimeric antigen receptor (CAR) T cells are patient-derived T cells engineered to express a fusion protein that directs them to target a tumor-associated antigen. The tumor-associated antigen CD19 is expressed on tumor cells in these conditions as well as on healthy cells of the B cell lineage. This results the "on-target off-tumor" effect of profound B cell depletion in these patients often with attendant hypogammaglobulinemia (HGG). Serious infections are common in this patient population and represent the main cause of non-relapse related mortality in CAR T cell treated patients.

Treatment of HGG with immunoglobulin replacement therapy (IRT) is a core component of infection prevention. Standard of care IRT can be administered intravenously (IVIG) or subcutaneously (SCIG). The proposed project will investigate frequency of bacterial infections, quality of life, treatment satisfaction, and adverse events in patients treated with CAR T-cell therapy who are treated with IVIG and SCIG.

Connect with a study center

  • University of Alberta

    Edmonton, Alberta T6G 2G3
    Canada

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.